Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Search
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The searchable portal provides a centralised location of cancer medicines that have been scored and published by ESMO.

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Agent
Tumour
Score
Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Tumour Stage Score Ref. Scorecard
Bevacizumab Paclitaxel Paclitaxel 1st line metastatic (no crossover) Breast Cancer Breast Cancer - Metastatic
2
Everolimus Exemestane Exemestane + placebo Metastatic after failure of aromatose inhibitor (with PFS> 6 months) (no crossover) Breast Cancer Breast Cancer HR+ Metastatic
2
Eribulin - Treatment of physician's choice 3rd line metastatic after anthracycline and taxane Breast Cancer Breast Cancer - Metastatic
2
Eribulin - Treatment of physician's choice 3rd line metastatic after anthracycline and taxane in HER2 negative patients Breast Cancer Breast Cancer HER2- Metastatic
1
Panitumumab FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin) FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin) 1st line metastatic colorectal cancer (post hoc KRAS, NRAS BRAF WT) Gastrointestinal Cancers Colon and Rectal Cancer - Metastatic
4
Panitumumab mFOLFOX6 (oxaliplatin, folinic acid, 5-fluorouracil) Bevacizumab + mFOLFOX6 (oxaliplatin, folinic acid, 5-fluorouracil) (Phase II study with unbalanced crossover) 1st line treatment Gastrointestinal Cancers Colon and Rectal Cancer RAS/BRAF-WT Metastatic
3
Cetuximab FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) 1st line metastatic (post hoc KRAS, NRAS WT) Gastrointestinal Cancers Colon and Rectal Cancer RAS-WT Metastatic
4
Cetuximab - Best supportive care Refractory metastatic KRAS-WT Gastrointestinal Cancers Colon and Rectal Cancer KRAS-WT Metastatic
4
Bevacizumab IFL (irinotecan, leucovorin, fluorouracil) IFL (irinotecan, leucovorin, fluorouracil) + placebo 1st line treatment Gastrointestinal Cancers Colon and Rectal Cancer - Metastatic
3
Panitumumab FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) 2nd line treatment Gastrointestinal Cancers Colon and Rectal Cancer RAS-WT Metastatic
3
Legal
Useful links
Subscribe to ESMO newsletters

Receive information and updates on ESMO’s scientific and educational resources, events, members activities.

To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH
© Copyright 2020 European Society for Medical Oncology All rights reserved worldwide.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings